This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
by Zacks Equity Research
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen
by Zacks Equity Research
Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen are included in this Analyst Blog.
Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?
by Zacks Equity Research
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024
by Zacks Equity Research
RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen
by Zacks Equity Research
Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen are included in this Analyst Blog.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
by Zacks Equity Research
Novo Nordisk (NVO) closed at $116.47 in the latest trading session, marking a -0.73% move from the prior day.
Is Pfizer's Attractive Valuation Enough to Invest in the Stock?
by Kinjel Shah
PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
by Zacks Equity Research
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
by Ahan Chakraborty
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
by Zacks Equity Research
The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
by Zacks Equity Research
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?
by Kinjel Shah
JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
by Sundeep Ganoria
VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.
Lilly Loses Around $14B This Week: How to Play LLY Stock
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR
by Zacks Equity Research
Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top Analyst Blog.
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
by Sanghamitra Saha
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.
FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List
by Zacks Equity Research
The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
AZN or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AZN vs. NVO: Which Stock Is the Better Value Option?
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
by Zacks Equity Research
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
Implied Volatility Surging for Novo Nordisk (NVO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Novo Nordisk (NVO) stock based on the movements in the options market lately.